Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 110,000 | 296.4% |
| Gross Profit | -14M | 33.2% |
| Cost of Revenue | 14M | 33.9% |
| Operating expense | 37M | 7.3% |
| Net Income | -25M | 12.1% |
| EBITDA | -36M | 7.3% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 938M | 0.9% |
| Total Liabilities | 26M | 2.2% |
| Total Equity | 911M | 1% |
| Shares Outstanding | 111M | 0.6% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -22M | 23% |
| Cash from investing | 26M | 120.5% |
| Cash from financing | 2.5M | 13.2% |
EPS
Financial Highlights for Viking Therapeutics in Q3 '24
Viking Therapeutics reported a revenue of 110,000, which is a 296.4% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at -14M, marking a -33.2% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 14M, a 33.9% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 37M, showing a 7.3% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -25M, showing a -12.1% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -36M, showing a -7.3% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Viking Therapeutics faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
